Industry
Biotechnology
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Loading...
Open
3.00
Mkt cap
70M
Volume
1M
High
3.30
P/E Ratio
-0.03
52-wk high
7.97
Low
2.80
Div yield
N/A
52-wk low
1.30
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 1:02 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 1:16 pm
Portfolio Pulse from Benzinga Insights
March 13, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
February 29, 2024 | 1:55 pm
Portfolio Pulse from Benzinga Newsdesk
February 29, 2024 | 12:50 am
Portfolio Pulse from Avi Kapoor
February 26, 2024 | 7:48 am
Portfolio Pulse from Benzinga Insights
February 23, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
February 23, 2024 | 9:11 pm
Portfolio Pulse from Happy Mohamed
February 14, 2024 | 9:32 pm
Portfolio Pulse from Benzinga Insights
February 09, 2024 | 9:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.